Venus Remedies Ltd (VENUSREM)

Venus Remedies Expands Reach of Oncology Drugs in Ukraine - 18 Mar, 2024

Venus Remedies has received marketing authorizations from Ukraine for three cancer drugs, with plans to increase exports by 20% in the next year. The company is also awaiting approval on another 10 applications.

Venus Remedies Ltd Stock Price Falls by 26% in a Month - 14 Mar, 2024

The Venus Remedies Ltd stock price has fallen by 26% over the last month, but it has gained 86% in the past year. The company's P/E ratio of 13.3x is lower than many Indian companies, which could be due to expectations of earnings degradation. Further investigation is required to determine if this is justified.

Venus Remedies Secures UNICEF Approval for Antibiotic Supply - 11 Mar, 2024

Venus Remedies has received good manufacturing practices (GMP) approval from UNICEF to supply Cephalosporin antibiotics for treating infections. The company's Q3 FY24 net profit increased by 108.2% YoY, while net sales grew by 22.7%. The stock shed 0.69% to end at Rs 331.45 on the BSE.

Venus Remedies Receives Marketing Authorisation for Oncology Drugs in Ukraine - 08 Mar, 2024

Venus Remedies has received marketing authorisation for its oncology drugs in Ukraine. The company also received ₹7.5 crore under the Government's Production Linked Incentive scheme for 2022-23. Venus Remedies' stock closed at ₹332.65, up by 1.54% on the NSE.

Venus Remedies Receives First Disbursement Under PLI Scheme - 06 Mar, 2024

Venus Remedies Ltd has received its first disbursement of Rs 7.5 crore under the Indian Government's Production Linked Incentive (PLI) scheme for FY 2022-23, covering 75% of the total incentive due to the company. The disbursement will boost manufacturing capabilities and foster product diversification.